Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Javle

Showing results (91-100 of 343) with videos related to

Pageof 35
Sort By:
Investigational New Drugs|February 12, 2026
Phase I results of a multicenter, open-label, dose de-escalation and expansion study of gemcitabine and cisplatin with ivosidenib or pemigatinib for advanced cholangiocarcinomaFen Saj, Tanios S Bekaii-Saab, Milind Javle, et al.
Annals of Surgical Oncology|July 27, 2016
Laparoscopic Management of Gallbladder Cancer: A Stepwise ApproachSuguru Yamashita, Evelyne Loyer, Yun Shin Chun, et al.
International Journal of Gastrointestinal Cancer|February 10, 2007
Combined hepatocholangiocarcinoma: case-series and review of literatureVishal Bhagat, Milind Javle, Jihnhee Yu, et al.
Transplantation|March 29, 2020
Liver Transplantation for Cholangiocarcinoma and Mixed Hepatocellular Cholangiocarcinoma: Working Group Report From the ILTS Transplant Oncology Consensus ConferenceGonzalo Sapisochin, Milind Javle, Jan Lerut, et al.
American Journal of Clinical Oncology|October 11, 2008
Pilot study of gefitinib, oxaliplatin, and radiotherapy for esophageal adenocarcinoma: tissue effect predicts clinical responseMilind Javle, Amitkumar Pande, Renuka Iyer, et al.
Investigational New Drugs|May 8, 2020
Phase I study of DFP-11207, a novel oral fluoropyrimidine with reasonable AUC and low C<sub>max</sub> and improved tolerability, in patients with solid tumorsJaffer A Ajani, Milind Javle, Cathy Eng, et al.
Hepato-Gastroenterology|November 10, 2004
Nuclear survivin expression predicts poor outcome in cholangiocarcinomaMilind M Javle, Dongfeng Tan, Jihnhee Yu, et al.
Journal of Gastrointestinal Oncology|December 2, 2014
Second-line systemic treatment for advanced cholangiocarcinomaJane E Rogers, Lindsey Law, Van D Nguyen, et al.
British Journal of Cancer|June 4, 2009
Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II studyM Javle, J Yu, C Garrett, et al.
Cancer Treatment Reviews|March 24, 2020
Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisationAvani Athauda, Caroline Fong, David K Lau, et al.
Pageof 35

Showing results (91-100 of 343) with videos related to

Sort By:
Pageof 35
Investigational New Drugs|February 12, 2026
Phase I results of a multicenter, open-label, dose de-escalation and expansion study of gemcitabine and cisplatin with ivosidenib or pemigatinib for advanced cholangiocarcinomaFen Saj, Tanios S Bekaii-Saab, Milind Javle, et al.
Annals of Surgical Oncology|July 27, 2016
Laparoscopic Management of Gallbladder Cancer: A Stepwise ApproachSuguru Yamashita, Evelyne Loyer, Yun Shin Chun, et al.
International Journal of Gastrointestinal Cancer|February 10, 2007
Combined hepatocholangiocarcinoma: case-series and review of literatureVishal Bhagat, Milind Javle, Jihnhee Yu, et al.
Transplantation|March 29, 2020
Liver Transplantation for Cholangiocarcinoma and Mixed Hepatocellular Cholangiocarcinoma: Working Group Report From the ILTS Transplant Oncology Consensus ConferenceGonzalo Sapisochin, Milind Javle, Jan Lerut, et al.
American Journal of Clinical Oncology|October 11, 2008
Pilot study of gefitinib, oxaliplatin, and radiotherapy for esophageal adenocarcinoma: tissue effect predicts clinical responseMilind Javle, Amitkumar Pande, Renuka Iyer, et al.
Investigational New Drugs|May 8, 2020
Phase I study of DFP-11207, a novel oral fluoropyrimidine with reasonable AUC and low C<sub>max</sub> and improved tolerability, in patients with solid tumorsJaffer A Ajani, Milind Javle, Cathy Eng, et al.
Hepato-Gastroenterology|November 10, 2004
Nuclear survivin expression predicts poor outcome in cholangiocarcinomaMilind M Javle, Dongfeng Tan, Jihnhee Yu, et al.
Journal of Gastrointestinal Oncology|December 2, 2014
Second-line systemic treatment for advanced cholangiocarcinomaJane E Rogers, Lindsey Law, Van D Nguyen, et al.
British Journal of Cancer|June 4, 2009
Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II studyM Javle, J Yu, C Garrett, et al.
Cancer Treatment Reviews|March 24, 2020
Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisationAvani Athauda, Caroline Fong, David K Lau, et al.
Pageof 35